Cyclosporine for omalizumab-refractory chronic urticaria: a report of five cases

BACKGROUND: While both the AAAAI/ACAAI and the EAACI/GA(2)LEN/EuroGuiDerm/APAAACI guidelines recommend starting cyclosporine for patients with chronic urticaria who have had an inadequate response to omalizumab, many clinicians are hesitant to initiate cyclosporine due to paucity of clinical data. T...

Descripción completa

Detalles Bibliográficos
Autores principales: LaCava, Anthony F., Fadugba, Olajumoke O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10466821/
https://www.ncbi.nlm.nih.gov/pubmed/37644553
http://dx.doi.org/10.1186/s13223-023-00820-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10466821/
https://www.ncbi.nlm.nih.gov/pubmed/37644553
http://dx.doi.org/10.1186/s13223-023-00820-4

Ejemplares similares